Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial

NCT04642261 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT04642261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04642261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Empagliflozin on Liver Fat in Non-alcoholic Fatty Liver Disease Patients Without Diabetes Mellitus: a Randomized, Double-blind, Placebo-controlled Trial
Lead sponsor
The University of Hong Kong
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2021
Completion date
June 30, 2023
Enrollment
98 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease